Amended Current Report Filing (8-k/a)
January 10 2018 - 6:12AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January 9, 2018
MELINTA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
|
001-35405
|
|
45-4440364
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
300 George Street, Suite 301, New Haven, CT
|
|
06511
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code (312)
767-0291
Check the appropriate box below
if the
Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b) under
the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c) under
the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Introductory Note
This amendment is being filed solely to
re-file
Exhibit 10.2, the Facility Agreement, dated as of January 5, 2018,
by and among Melinta Therapeutics, Inc., the other loan parties thereto, and Cortland Capital Market Services LLC, as Agent, to the Current Report on
Form 8-K
filed on January 9, 2018, in order to
attach the additional Exhibits and Schedules thereto.
Item 9.01.
|
Financial Statements and Exhibits.
|
(a) Exhibits.
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Date: January 9, 2018
|
|
|
|
Melinta Therapeutics, Inc.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Paul Estrem
|
|
|
|
|
|
|
Paul Estrem
|
|
|
|
|
|
|
Chief Financial Officer
|
- 3 -
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From Apr 2023 to Apr 2024